Myasthenia gravis. a rare disease in children. occurs in a variety of forms. The aetiology and clinical presentations are reviewed. Eight patients who were studied with electromyography are presented. The results show that. in general. patients with the usual pattern of disease are resistant to suxamethonium (ED95 3-4 times normal) and are sensitive to nondepolarizing relaxants. When the latter are used it is advisable to administer small increments with neuromuscular monitoring. One patient with the disease localised to the eyelid had normal EMG responses when monitored on the hand with ulnar nerve stimulation.
Myasthenia gravis is a condition of particular interest to anaesthetists because it involves the neuromuscular junction -the site of action of some of our most commonly used drugs. This paper presents a brief review of the condition and the various forms encountered, particularly in children. I ,2 The anaesthetic implications, especially with reference to the use of muscle relaxants and the effect of inhalation agents are considered and the results of our electromyographic studies carried out during anaesthesia are presented.
REVIEW OF MY ASTHENIA GRAVIS DEFINITION Myasthenia gravis (MG) in adults is an acquired autoimmune disease but this is not the case in the congenital varieties. There is a sustained production of acetylcholine receptor antibodies (AChRAB) causing a reduction of available acetyl choline (ACh) receptors at the neuromuscular junction (NMJ). ACh appears to be normal.
The resulting impairment of neuromuscular transmission is manifest as a reduced amplitude of the End Plate Potential and, clinically, as generalised or selective weakness, especially of ocular muscles, The AChR antibodies can be shown to be present in 80-90% of cases. These are produced by B-cells in a T-cell dependant manner. The exact nature of the involvement of the thymus is complex and uncertain. IgG and complement components are deposited on the post-synaptic membrane, where their mechanisms of action may include increased breakdown of ACh receptors (with crosslinking), blocking of ACh receptors, or damaging the ACh receptors.
CLINICAL 1. Adults
An uncommon condition, MG has an incidence of about five per million with a female predominance (3:2) . It can present at any age, but the peak incidence is during the third decade in females and during the sixth decade in males.
In adults, the usual clinical features are ocular (ptosis, diplopia), cranial nerve (bulbar signsdysphagia, dysarthria, drooling, jawdrop, poor expression), peripheral (general weakness, exertional dyspnoea) or general (all of the above). Tendon reflexes are usually present and muscle atrophy is only occasional. The initial presentation is usually either ocular (40%, of which about 1/3 will remain only ocular) or generalised (40%), with peripheral and bulbar features being less common (about 10% each).
When progression of the disease to involve other muscle groups does occur, it usually does so within three years of presentation. The disease can affect all muscle groups in its most advanced stages. The course of the disease is characterised by variable, fluctuating symptoms and signs. It may be exacerbated by exertion, infections and emotional upsets.
Thymic hyperplasia is present in 2/3 of cases and thymoma is present in about 15%. There may be other associated autoimmune diseases (SLE, thyroid disease, etc).
Classifications of the disease have been proposed based on severity (Osserman -Groups I-IV) orthe presence of thymoma (Type I-Ill).
Children
Myasthenia gravis in children is rare and can be divided into three groups:
(1) Transient neonatal MG (2) Congenital MG syndromes (3) Juvenile (autoimmune) MG 2.1 Transient neonatal myasthenia gravis occurs in babies born to mothers with myasthenia gravis, although only about 10-15% of such neonates develop signs. It is due to either passive AChR antibody transfer to the fetus, or to immune cell transfer to the fetus. In either case, AChR antibodies can be demonstrated in these neonates. The onset is within 72 hours of birth, and the features are cranial nerve dysfunction (ptosis, facial weakness, poor cry, poor feeding and poor swallowing), hypotonia and respiratory distress. The condition usually resolves after five weeks and responds to anticholinesterases. 2.2 There are several congenital myasthenic syndromes which differ from the autoimmune and the neonatal forms of myasthenia gravis. 2 These syndromes are due to an impaired safety margin of neuromuscular transmission from other causes. ACh receptor antibodies are usually not present and there is no maternal myasthenia gravis. The normal safety margin of neuromuscular transmission is due to the difference between the actual endplate potential generated and the minimal end plate potential necessary to trigger the muscle fibre action potential. Under normal conditions there is a safety margin due to an excess of acetylcholine (ACh) quanta released. (a) Familial infantile myasthenia is an autosomal recessive condition presenting in early infancy Anaesthesia and intensive Care. Vol. 18. No. 4. November. 1990 with ocular, bulbar and respiratory features. It is thought to be due to a progressive decrease in ACh released from synaptic vesicles with repetitive stimulation. It may be caused by impaired choline re-uptake, impaired ACh synthesis, impaired transport, or all three. It responds well to anticholinesterases. Myasthenic crises often occur (during febrile illness, overexertion etc) and may require respiratory support. Improvement often occurs with age. (b) Congenital endplate acetylcholinesterase deficiency is a sporadic, very rare condition due to total absence of acetyl cholinesterase at the neuromuscular junction coupled with abnormally small motor nerves with reduced ACh quanta. l The absence of acetylcholinesterase means that the endplate potential remains above threshold for an abnormally long time and can cause repeated muscle action potentials. The condition is severe, disabling and refractory to anticholinesterases. (c) Slow channel syndrome is an autosomal dominant condition (with high penetrance and variable expression) with variable age of onset, severity and muscle distribution. It usually has intermittent exacerbations and long periods of remission. It is thought to be due to prolonged endplate potentials associated with a prolonged open time of the AChR ion channel. Excessive calcium influx, causing activation of proteases and phospholipases, is thought to explain the secondary wasting of selected muscles and the decreased number of acetyl choline receptors at the folds. It is refractory to anticholinesterases. (d) Congenital endplate acetylcholine receptor deficiency is an extremely rare, poorly characterised syndrome of uncertain inheritance where the number of acetyl choline receptors can be shown to be reduced. The exact nature and aetiology remains to be evaluated.
There are also other partially characterised congenital myasthenic syndromes which have been reported. 1 
Juvenile myasthenia gravis occurs in children
of one year or older, predominantly in females.
It has similar features to the adult disease. Because the condition is so rare, there are few large series available. Rodriguez et af.2 reviewed 149 patients with the following results:
The mean age of onset was 13 years and the spontaneous remission rate (no symptoms on no medication) was 22.4 per 1000 person-years. Remission was less common in patients with peripheral weakness.
Thymectomy was performed in those with severe disease, who made up just over half the patients. It resulted in an increased remission rate (260 per 1000 person-years) during the following year. This decreased to the spontaneous remission rate after three years. The incidence of post thymectomy remission appeared higher for those who underwent thymectomy within twelve months of presentation, for those with onset between 12-16 years, for those with bulbar signs without ocular signs and for those with associated autoimmune diseases. The histological findings of the thymus appeared not to correlate with surgical response.
The most common autoimmune diseases associated with juvenile myasthenia gravis were rheumatoid arthritis, diabetes mellitus and thyroid disease. Asthma, epilepsy and neoplasias were also more common in the patients studied.
The 20-year survival was 82% (expected = 98%) with most deaths occurring early in the disease course and being due to myasthenia gravis. Thymectomy improved survival slightly. Thus, the overall prognosis for remission and survival is better than for adults and appeared improved by thymectomy. The exact beneficial effect of steroids in this group was hard to assess.
Diagnosis
Diagnosis of myasthenia gravis is primarily a clinical diagnosis but confirmation is usually sought with the following: TREATMENT OF MYASTHENIA GRAVIS 1. Anticholinesterases: Pyridostigmine is usually preferred to neostigmine, because of its longer duration of action and fewer muscarinic sideeffects. Its effect lasts for three to four hours. Slow release preparations are available but are usually only used at night in circumstances where muscle weakness would result in bulbar or respiratory difficulty. Atropine is rarely necessary to counteract muscarinic side effects.
Episodes of myasthenic crisis (worsening features in spite of increasing dosages) can be either cholinergic (usually with muscarinic features such as increased secretions and bradycardia) or myasthenic (weakness improved with intravenous edrophonium). It may be necessary to stop the anticholinesterase and give supportive treatment, including ventilation and even curarisation. This has been useful in some advanced cases. 4 2. Surgery: Thymectomy is often performed with beneficial results, especially when thymic hyperplasia is present or in severe cases with high antibody titres. In adults, the presence of a thymoma is an indication for surgery. The immediate postoperative period can be one of extreme instability in the course of the disease. Ventilation may be required and careful adjustment of anticholinesterase dosage made. 3. Immunosupression: Many patients will benefit from the administration of steroids, usually with a low initial dose. Azathioprine will also improve about half of recipients, but side-effects (blood dyscrasias, liver dysfunction) may be a problem. Given either alone or together, these drugs will improve about 90% of recipients, but therapy is often long term and may result in serious side-effects. 4. Plasmapheresis can be used to temporarily decrease acetylcholine receptor antibodies in severe, fulminating cases where other treatments have failed, or to improve a patient's strength prior to thymectomy.
Future treatment:
Cyclosporin has been tried in humans and does appear to decrease acetylcholine receptor antibodies and improve the condition, but the improvement is not consistent or sustained.
Research is currently being aimed at 'anti-idiotypes' (i.e. anti-antibodies) and manipulation and use of suppressor T -cells (specific for B-cells producing ACh receptor antibodies). The exact structure and amino acid sequence of the acetylcholine receptor is being studied for possible specific areas of interaction with the antibodies.
ANAESTHETIC IMPLICATIONS
The tendency in the past was to avoid muscle relaxants in myasthenic patients, particularly when a degree of weakness occurred on cessation of anticholinesterase therapy. The principle employed was to stop drug therapy, usually pyridostigmine, the night before surgery and then to rely on inhalational anaesthesia, even to intubate the patient. It was considered easier to avoid muscle relaxants and the problems that might be precipitated using neostigmine for reversal. The dose requirement of the latter is uncertain for each patient and excess may result in cholinergic crises.
When the muscle relaxants were used, patients were often electively ventilated postoperatively. Resting the neuromuscular junction was considered beneficial to some patients with myasthenia gravis, especially when they had become difficult to manage with drugs. 4 Factors used for predicting the need for postoperative respiratory support include the duration of the disease being more than six years, the presence of other respiratory disease and the requirement of high doses of anticholinesterases. 5 The advent of electromyography in our department and the more widespread monitoring of neuromuscular blockade led us to study the responses to normal doses of suxamethonium and to incremental doses of nondepolarizing muscle gravis. Seven of these patients had muscle relaxants and one infant, undergoing myringotomies and a muscle biopsy, received halothane. Information regarding the patients and their responses to relaxants is summarised in Table 1. The dose-responses to muscle relaxants were calculated on a log-probit dose-response graph and a line was drawn parallel to the normal response lines derived by Meretoja to determine ED95 for alcuronium, d-tubocurarine,1 atracurium 8 and suxamethonium. 9 Three patients received suxamethonium followed by alcuronium (Figure 1 ) or d-tubocurarine ( Figure 2) . We have recently shown that the prior administration of suxamethonium does not alter the degree or duration of neuromuscular block produced by alcuronium in normal children. lo Figure 3 demonstrates the log-probit graph with results of two of the patients who received alcuronium compared with the normal alcuronium responses for the age groups one to 10 and 11 to 16 years. The extrapolated ED95S of alcuronium were 40-45 ~g/kg in three of our patients. These doses were 14-17 per cent of normal for alcuronium in similar aged children. The patients who received d-tubocurarine respectively showed a nearly normal (80 per cent) ( Figure 4 ) and a markedly reduced dose requirement (10 per cent) ( Figure 2) . The dose response of the patient given atracurium was 60 per cent of normal ( Figure 5 ). One 34 kg child, undergoing thymectomy, had two doses of alcuronium 30 ~g/kg to reach 97% neuromuscular block ( Figure 6 ). His relaxant was not reversed as it was decided to ventilate him postoperatively. One 14-year-old boy had several years' history of ocular myasthenia gravis with ptosis as his only presenting complaint. He was treated with pyridostigmine, but still had some ptosis. The drug was stopped six hours before his operation. When he presented for thymectomy he had normal responses to suxamethonium and alcuronium when the EMG was monitored on the hand, supporting the view that his condition was the localised ocular variety. Patients with myasthenia gravis are clinically resistant to suxamethonium. Figure 7 shows a myasthenic response compared to that of a normal child who was given suxamethonium 1 mg/kg followed by alcuronium 0.2 mglkg. This caused the same degree of neuromuscular block as 0.03 mg/kg in the myasthenic child. In three patients, our EMG studies demonstrated that the ED95 of suxamethonium was three to four times normal. 9 Table 1 also summarises the extrapolated ED95 for the various relaxants used in our patients. These studies have demonstrated that, with electromyographic monitoring, muscle relaxants can be used safely, provided the nondepolarizing relaxants are given in small increments to establish the appropriate dose. Neostigmine also should be administered in small increments so as to avoid a cholinergic crisis and the response to this drug should also be monitored. Atracurium would appear to be the muscle relaxant of choice because of its short action, rapid breakdown and the possibility that neostigmine may not be needed or may only be required in small doses, thus reducing complications. I 1, 12 When inhalational anaesthetics are used the EMG baseline tends to drift more than is expected in normal patients (10-30%). It is not yet clear whether this is due to a central anaesthetic mechanism, altered skin impedence, an action on the neuromuscular junction or on the muscle itself, Anaesthesia and Intensive Care. Vol. 18, No. 4, November. 1990 possibly interfering with the normal generation of the action potential. Fade would be expected following a tetanus or following repeated train-of-four stimulation in myasthenic patients who did not receive relaxants. 3 A 21-month-old girl with a presumptive diagnosis of myasthenia gravis was anaesthetised with halothane for muscle biopsy and myringotomies. Single twitch stimulation of the distal ulnar nerve at 0.1 Hz resulted in a gradual decline of the baseline height to 50 per cent, but there was no fade on the train-of-four. Although this might suggest an alternative diagnosis, fade may not occur in all muscles in MG patients and is more likely to be present in the proximal rather than the hand muscles. However, the muscle biopsy showed some myopathic abnormalities, supporting the possibility of an alternative diagnosis. Monitoring twitch height and train-of-four may be of a diagnostic value, as well as a guide to drug dosage in these patients.
In conclusion, myasthenia gravis is a rare condition in children. The patients are often treated with anticholinesterases and sometimes with steroids. Neuromuscular monitoring is recommended if muscle relaxants are used, because of the variable response to them and the frequency of sensitivity to nondepolarizing relaxants. Reversal with neostigmine should also be monitored because of the uncertainty of response when these patients are already being treated with anticholinesterases.
If neuromuscular monitoring is not available, significant diminution of the action potential height can be expected with the use of inhalational agents and adequate relaxation can be produced for intubation with inhalational anaesthesia alone.
